PACIRA BIOSCIENCES INC (PCRX) Fundamental Analysis & Valuation

NASDAQ:PCRX • US6951271005

22.44 USD
+0.2 (+0.9%)
At close: Mar 10, 2026
22.44 USD
0 (0%)
After Hours: 3/10/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This PCRX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

6

Overall PCRX gets a fundamental rating of 6 out of 10. We evaluated PCRX against 193 industry peers in the Pharmaceuticals industry. PCRX has only an average score on both its financial health and profitability. PCRX may be a bit undervalued, certainly considering the very reasonable score on growth These ratings could make PCRX a good candidate for value investing.


Dividend Valuation Growth Profitability Health

6

1. PCRX Profitability Analysis

1.1 Basic Checks

  • PCRX had positive earnings in the past year.
  • In the past year PCRX had a positive cash flow from operations.
  • PCRX had positive earnings in 4 of the past 5 years.
  • Each year in the past 5 years PCRX had a positive operating cash flow.
PCRX Yearly Net Income VS EBIT VS OCF VS FCFPCRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M 100M 150M

1.2 Ratios

  • PCRX has a Return On Assets of 0.56%. This is in the better half of the industry: PCRX outperforms 79.27% of its industry peers.
  • Looking at the Return On Equity, with a value of 1.01%, PCRX belongs to the top of the industry, outperforming 81.35% of the companies in the same industry.
  • PCRX has a better Return On Invested Capital (2.67%) than 80.31% of its industry peers.
  • PCRX had an Average Return On Invested Capital over the past 3 years of 4.67%. This is significantly below the industry average of 13.09%.
Industry RankSector Rank
ROA 0.56%
ROE 1.01%
ROIC 2.67%
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
PCRX Yearly ROA, ROE, ROICPCRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • With a decent Profit Margin value of 0.97%, PCRX is doing good in the industry, outperforming 79.27% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PCRX has declined.
  • Looking at the Operating Margin, with a value of 5.33%, PCRX is in the better half of the industry, outperforming 79.27% of the companies in the same industry.
  • In the last couple of years the Operating Margin of PCRX has declined.
  • The Gross Margin of PCRX (79.39%) is better than 84.46% of its industry peers.
  • PCRX's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.33%
PM (TTM) 0.97%
GM 79.39%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
PCRX Yearly Profit, Operating, Gross MarginsPCRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PCRX Health Analysis

2.1 Basic Checks

  • PCRX has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • PCRX has less shares outstanding than it did 1 year ago.
  • The number of shares outstanding for PCRX has been reduced compared to 5 years ago.
  • PCRX has a better debt/assets ratio than last year.
PCRX Yearly Shares OutstandingPCRX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
PCRX Yearly Total Debt VS Total AssetsPCRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • Based on the Altman-Z score of 1.81, we must say that PCRX is in the distress zone and has some risk of bankruptcy.
  • PCRX's Altman-Z score of 1.81 is fine compared to the rest of the industry. PCRX outperforms 61.66% of its industry peers.
  • PCRX has a debt to FCF ratio of 2.72. This is a good value and a sign of high solvency as PCRX would need 2.72 years to pay back of all of its debts.
  • PCRX's Debt to FCF ratio of 2.72 is amongst the best of the industry. PCRX outperforms 91.71% of its industry peers.
  • PCRX has a Debt/Equity ratio of 0.54. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
  • PCRX has a Debt to Equity ratio of 0.54. This is in the lower half of the industry: PCRX underperforms 62.18% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 2.72
Altman-Z 1.81
ROIC/WACC0.32
WACC8.42%
PCRX Yearly LT Debt VS Equity VS FCFPCRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 4.54 indicates that PCRX has no problem at all paying its short term obligations.
  • The Current ratio of PCRX (4.54) is better than 62.69% of its industry peers.
  • A Quick Ratio of 3.28 indicates that PCRX has no problem at all paying its short term obligations.
  • PCRX has a Quick ratio of 3.28. This is comparable to the rest of the industry: PCRX outperforms 56.48% of its industry peers.
Industry RankSector Rank
Current Ratio 4.54
Quick Ratio 3.28
PCRX Yearly Current Assets VS Current LiabilitesPCRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PCRX Growth Analysis

3.1 Past

  • The earnings per share for PCRX have decreased strongly by -18.07% in the last year.
  • PCRX shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 3.64% yearly.
  • Looking at the last year, PCRX shows a very negative growth in Revenue. The Revenue has decreased by -16.32% in the last year.
  • Measured over the past years, PCRX shows a quite strong growth in Revenue. The Revenue has been growing by 11.08% on average per year.
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%

3.2 Future

  • Based on estimates for the next years, PCRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.64% on average per year.
  • Based on estimates for the next years, PCRX will show a small growth in Revenue. The Revenue will grow by 5.42% on average per year.
EPS Next Y16.65%
EPS Next 2Y20.6%
EPS Next 3Y14.23%
EPS Next 5Y10.64%
Revenue Next Year7.11%
Revenue Next 2Y8.4%
Revenue Next 3Y7.67%
Revenue Next 5Y5.42%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
PCRX Yearly Revenue VS EstimatesPCRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
PCRX Yearly EPS VS EstimatesPCRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

9

4. PCRX Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 8.53, the valuation of PCRX can be described as reasonable.
  • 92.23% of the companies in the same industry are more expensive than PCRX, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 26.25, PCRX is valued rather cheaply.
  • PCRX is valuated cheaply with a Price/Forward Earnings ratio of 7.31.
  • PCRX's Price/Forward Earnings ratio is rather cheap when compared to the industry. PCRX is cheaper than 92.75% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 24.39, PCRX is valued rather cheaply.
Industry RankSector Rank
PE 8.53
Fwd PE 7.31
PCRX Price Earnings VS Forward Price EarningsPCRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 92.23% of the companies in the same industry are more expensive than PCRX, based on the Enterprise Value to EBITDA ratio.
  • PCRX's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PCRX is cheaper than 94.82% of the companies in the same industry.
Industry RankSector Rank
P/FCF 6.65
EV/EBITDA 7.36
PCRX Per share dataPCRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • PCRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of PCRX may justify a higher PE ratio.
  • A more expensive valuation may be justified as PCRX's earnings are expected to grow with 14.23% in the coming years.
PEG (NY)0.51
PEG (5Y)2.35
EPS Next 2Y20.6%
EPS Next 3Y14.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PCRX Dividend Analysis

5.1 Amount

  • PCRX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PCRX Fundamentals: All Metrics, Ratios and Statistics

PACIRA BIOSCIENCES INC

NASDAQ:PCRX (3/10/2026, 8:00:01 PM)

After market: 22.44 0 (0%)

22.44

+0.2 (+0.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners118.41%
Inst Owner Change-2.59%
Ins Owners1.78%
Ins Owner Change16.65%
Market Cap908.60M
Revenue(TTM)726.41M
Net Income(TTM)7.03M
Analysts76.92
Price Target30.31 (35.07%)
Short Float %19.56%
Short Ratio8.18
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.46%
Min EPS beat(2)-38.21%
Max EPS beat(2)5.28%
EPS beat(4)3
Avg EPS beat(4)-7.2%
Min EPS beat(4)-38.21%
Max EPS beat(4)5.28%
EPS beat(8)6
Avg EPS beat(8)1.27%
EPS beat(12)7
Avg EPS beat(12)-1.33%
EPS beat(16)7
Avg EPS beat(16)-6.57%
Revenue beat(2)0
Avg Revenue beat(2)-3.64%
Min Revenue beat(2)-3.7%
Max Revenue beat(2)-3.59%
Revenue beat(4)0
Avg Revenue beat(4)-4.05%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-2.99%
Revenue beat(8)1
Avg Revenue beat(8)-2.33%
Revenue beat(12)1
Avg Revenue beat(12)-2.76%
Revenue beat(16)1
Avg Revenue beat(16)-2.75%
PT rev (1m)0%
PT rev (3m)-1.5%
EPS NQ rev (1m)-14.02%
EPS NQ rev (3m)-17.67%
EPS NY rev (1m)-11.73%
EPS NY rev (3m)-10.78%
Revenue NQ rev (1m)-3.31%
Revenue NQ rev (3m)-3.43%
Revenue NY rev (1m)-1.07%
Revenue NY rev (3m)-2.25%
Valuation
Industry RankSector Rank
PE 8.53
Fwd PE 7.31
P/S 1.25
P/FCF 6.65
P/OCF 5.98
P/B 1.31
P/tB 2.98
EV/EBITDA 7.36
EPS(TTM)2.63
EY11.72%
EPS(NY)3.07
Fwd EY13.67%
FCF(TTM)3.38
FCFY15.04%
OCF(TTM)3.75
OCFY16.73%
SpS17.94
BVpS17.12
TBVpS7.53
PEG (NY)0.51
PEG (5Y)2.35
Graham Number31.83
Profitability
Industry RankSector Rank
ROA 0.56%
ROE 1.01%
ROCE 3.38%
ROIC 2.67%
ROICexc 3.38%
ROICexgc 5.91%
OM 5.33%
PM (TTM) 0.97%
GM 79.39%
FCFM 18.81%
ROA(3y)-1.06%
ROA(5y)-0.04%
ROE(3y)-2.32%
ROE(5y)0.17%
ROIC(3y)4.67%
ROIC(5y)4.88%
ROICexc(3y)6.66%
ROICexc(5y)7.23%
ROICexgc(3y)14.37%
ROICexgc(5y)26.99%
ROCE(3y)5.91%
ROCE(5y)6.18%
ROICexgc growth 3Y-17.07%
ROICexgc growth 5Y-17.82%
ROICexc growth 3Y-9.16%
ROICexc growth 5Y-18.82%
OM growth 3Y-20.59%
OM growth 5Y-17.68%
PM growth 3Y-25.95%
PM growth 5Y-50.88%
GM growth 3Y4.23%
GM growth 5Y1.78%
F-Score8
Asset Turnover0.57
Health
Industry RankSector Rank
Debt/Equity 0.54
Debt/FCF 2.72
Debt/EBITDA 2.87
Cap/Depr 16.85%
Cap/Sales 2.11%
Interest Coverage 2.54
Cash Conversion 117.14%
Profit Quality 1942.86%
Current Ratio 4.54
Quick Ratio 3.28
Altman-Z 1.81
F-Score8
WACC8.42%
ROIC/WACC0.32
Cap/Depr(3y)16.8%
Cap/Depr(5y)48.87%
Cap/Sales(3y)1.96%
Cap/Sales(5y)3.77%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.07%
EPS 3Y0.51%
EPS 5Y3.64%
EPS Q2Q%-37.36%
EPS Next Y16.65%
EPS Next 2Y20.6%
EPS Next 3Y14.23%
EPS Next 5Y10.64%
Revenue 1Y (TTM)-16.32%
Revenue growth 3Y2.9%
Revenue growth 5Y11.08%
Sales Q2Q%5.14%
Revenue Next Year7.11%
Revenue Next 2Y8.4%
Revenue Next 3Y7.67%
Revenue Next 5Y5.42%
EBIT growth 1Y-65.3%
EBIT growth 3Y-18.29%
EBIT growth 5Y-8.56%
EBIT Next Year17.68%
EBIT Next 3Y14.84%
EBIT Next 5Y7.61%
FCF growth 1Y-23.55%
FCF growth 3Y5.86%
FCF growth 5Y28.37%
OCF growth 1Y-19.75%
OCF growth 3Y1.51%
OCF growth 5Y14.57%

PACIRA BIOSCIENCES INC / PCRX FAQ

What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?

ChartMill assigns a fundamental rating of 6 / 10 to PCRX.


What is the valuation status for PCRX stock?

ChartMill assigns a valuation rating of 9 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.


How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?

PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 6 / 10.


What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 8.53 and the Price/Book (PB) ratio is 1.31.